Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …

Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the
leading causes of chronic liver disease worldwide. NAFLD and ALD share …

Alongside the liver, white adipose tissue (WAT) is critical in regulating systemic energy
homeostasis. Although each organ has its specialised functions, they must work …

Non-alcoholic fatty liver disease (NAFLD), currently the leading cause of global chronic liver
disease, has emerged as a major public health problem, more efficient therapeutics of which …

Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Liver fibrosis, as an excess deposition of extracellular matrix (ECM) components, results
from chronic liver injury as well as persistent activation of inflammatory response and of …

Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …

Recent data have shown that liver fibrosis can regress even at later stages of cirrhosis and
shifting the immune response from pro-inflammatory towards a resolutive profile is …

Adult hepatocyte identity is constructed throughout embryonic development and fine-tuned
after birth. A multinodular network of transcription factors, along with pre-mRNA splicing …

Background With the rising global prevalence of fatty liver disease related to metabolic
dysfunction, the association of this common liver condition with chronic kidney disease …